Disruption of Cell-Cell Adhesion Enhances Antibody-dependent Cellular Cytotoxicity: Implications for Antibody-based Therapeutics of Cancer

Shane K. Green, Mikael C. I. Karlsson, Jeffrey V. Ravetch, and Robert S. Kerbel

ABSTRACT

Resistance to antibody-based anticancer approaches has become of considerable interest because of the rapidly growing clinical use of several different monoclonal antibodies as therapeutic agents, coupled with the recent finding that their efficacy may be attributable in part to their participation in host antibody-dependent cellular cytotoxicity. In this proof-of-concept study, we demonstrate the novel ability of an antiadhesive antibody (SHE78–7), targeted at the potent homophilic cell adhesion molecule E-cadherin, to play a dual role as participant in, and sensitizing agent for, host immune-mediated antitumor activity. SHE78–7 disrupted preformed multicellular aggregates (spheroids) of HT29 colon carcinoma cells both in vitro and in vivo in an ascites tumor xenograft model, but had no direct antitumor effect in vitro. In vivo, however, i.p. injection of SHE78–7 significantly prolonged the survival of nude mice carrying established i.p. HT29 xenografts, most notably when injections were given biweekly. This antitumor effect was dependent on the antitumor effect of SHE78–7 and could be effectively recapitulated via treatment with a combination of nondisruptive anti-hMHC-I antibodies, capable of recruiting an Fc-mediated immune response but ineffective as a monotherapy and antiadhesive F(ab)’2 fragments of SHE78–7. Furthermore, additional therapy experiments using such F(ab)’2 fragments, or mice lacking activating FcγRIII receptors or inhibitory FcγRIIB, unequivocally indicated a role for host antibody-dependent cellular cytotoxicity, mediated by FcγRIII and negatively regulated by FcγRIIB. Taken together, the results suggest a possible means of improving antibody-based therapies of cancer, namely targeting antigens, selectively expressed or up-regulated by target cancer cells, which mediate cell-cell adhesive functions.

INTRODUCTION

Numerous studies, spanning a period of 3 decades, have demonstrated that human cancers, growing as three-dimensional multicellular masses (i.e., solid tumors in vivo, spheroids in vitro, and so forth), exhibit adhesion-dependent multicellular resistance to a diverse array of anticancer therapeutic approaches, including many traditional chemo- and radiotherapies (1–9). In addition, cell-cell adhesion profoundly attenuates the efficacy of host defense mechanisms and immunotherapeutic modalities, including antibodies (10), immunotoxins (11, 12), lymphokine-activated killer cells (13, 14), IFNs (15), and complement (16, 17), at eliminating tumor cells grown in a three-dimensional context. Previous preclinical studies have shown that multicellular resistance to chemo- and radiotherapy can be pharmacologically reversed by using antiadhesive agents to disrupt cell-cell contacts, thereby disturbing the integrity of cancer cell spheroids in vitro or i.p. avascular tumor cell clusters in vivo (4). However, it remains unclear whether this antiadhesive strategy could similarly sensitize tumor cells to other therapeutic modalities. Whereas chemo- and radioresistance in spheroids may be because of a number of factors including those arising as a result of adhesion-mediated signaling events (6, 18, 19), adhesion-mediated resistance to immunotherapeutics has been shown to be largely, if not entirely, the result of restricted penetration of immune effectors into multicellular tumor masses (11–17). As such, we reasoned that antiadhesives might indeed be used not only as chemo- and radiosensitizing agents, but also as immunosensitizers, by providing increased accessibility of tumor cells for endogenous and/or exogenous immune effector challenges.

The increasing clinical use of chimeric or humanized monoclonal antibodies for cancer treatment has stimulated research endeavors aimed at improving the efficacy of such drugs (20, 21). This holds especially true in light of recent work in FcγR3−/− knockout mice, which demonstrated that some antibodies approved for clinical use in cancer treatment, namely Rituxan (22) and Herceptin (23, 24), may owe much of their antitumor efficacy in vivo to their involvement in ADCC (25). It follows that antibodies that target cell adhesion molecules expressed by cancer cells could represent particularly promising antiadhesive agents for use as both immunotherapeutic and sensitizing agents, as they themselves could play an active role in any enhanced immune response (and coincidentally, as sensitizers to enhance the efficacy of other therapeutic modalities, including gene therapy, radiation, and chemotherapy).

We have reported previously the use of one such antiadhesive antibody, namely a particularly effective monoclonal antibody against E-cadherin, called SHE78–7 (26), to prevent spheroid formation of a number of E-cadherin-expressing human tumor cell lines when plated in three-dimensional culture in vitro (19). The purpose of the present study was to examine the ability of SHE78–7 to act as an immunotherapeutic antibody to prolong the survival of nude mice carrying i.p. xenografts of HT29 human colorectal carcinoma and to determine whether any such action is achieved by rendering the tumor cells more susceptible to host ADCC via the antiadhesive properties of the antibody.

By using a human tumor xenograft system, the antibody assumes tumor-specific qualities, and host toxicity is avoided. This would not be possible in a clinical situation, when targeting a molecule such as E-cadherin; as such, the experimental model we used was designed as a proof-of-concept preclinical model in which to demonstrate the possible antitumor efficacy and therapeutic advantages of exploiting cell adhesion molecules, selectively or preferentially expressed by tumor cells, for antibody-based therapeutics.

MATERIALS AND METHODS

Animals. Female NIH Swiss nu/nu mice used in antiadhesive disruption (of tumor aggregates) and survival experiments were obtained from Charles River Laboratories, Inc.,ilmington, Delaware.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/20/02; accepted 10/18/02.

1 Supported by a grant from the National Cancer Institute of Canada (to R. S. K.). S. K. G. was supported by PGSA and PGSB studentships from the Natural Sciences and Engineering Research Council of Canada, and an OGSST award from the Government of Ontario. J. V. R. and M. C. I. K. are funded by the NIH and the Swedish Cancer Society, respectively.

2 To whom requests for reprints should be addressed, at Molecular and Cellular Biology Research, Research Building, S-218, Sunnybrook and Women’s College Health Sciences Center, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Phone: (416) 480-5711; Fax: (416) 480-5703; E-mail: robert.kerbel@swchsc.on.ca.

3 The abbreviations used are: FcγR (IB/II/III); Fcγ receptor (type IIb or IIId); (m)Ab, monoclonal antibody; ADCC, antibody-dependent cellular cytotoxicity; CDC; complement-dependent cytotoxicity; GFP, green fluorescent protein; hCG, human chorionic gonadotropin; polyHEMA, poly(2-hydroxyethylmethacrylate).
River (St. Constant, Quebec, Canada) or Taconic (Germantown, NY). Wild-type control mice used in FgR experiments (IIB/III) –/– experiments were female BALB/c-nu/nu mice (Taconic); corresponding FgRRII –/– and FgRRII+/− female BALB/c-nu/nu mice were made by Toshiyuki Takai (Tohoku University, Sendai, Japan) as described previously (27). Mice were approximately 6–10 weeks old at the time of tumor cell injections. Animal care was in accordance with institutional guidelines.

Antibodies. SHE7–7 monoclonal antibody (murine IgG2a) against E-cadherin (26) and Fab(−)2 fragments thereof were generously provided by Takara Shuzo Co., Ltd. (Shiga, Japan). Fab(−)2 fragments were generated by pepsin digestion of 10 mg of SHE7–7 antibody followed by passage through a protein A column; purity was verified by SDS-PAGE. Purified, preservative-free antihuman-MHC-I antibody (α-hIL4-ABC, clone W6/32, murine IgG2a) was obtained from Serotec (Raleigh, NC). Nonspecific murine myeloma IgG2a (Zymed, San Francisco, CA) was dialyzed in serum-free RPMI 1640 (Life Technologies, Inc., Burlington, Ontario, Canada) using Slide-a-Lyzer dialysis cassettes (Serotec, Raleigh, NC) to remove NaN3 before use.

Cell Lines. HT29 and CaOV-3 cells were purchased from the American Type Culture Collection (Rockville, MD). HT29–GFP–hCG and CaOV–3 cells were maintained in RPMI 1640 or DMEM (Life Technologies, Inc.), respectively, supplemented with 10% fetal bovine serum (Life Technologies, Inc.) in a humidified atmosphere at 37°C in 5% CO2. HT29 cells with stable expression of GFP, to aid in cell tracking in vivo, were generated by transfection of pEGFP-N1 (Clontech Laboratories Inc., Windsor, Ontario, Canada) into HT29 cells using LipofectAMINE 2000 (Life Technologies, Inc.) followed by selection in G418; stable GFP expression was verified after several passages in culture by flow cytometry (FACScan; Becton Dickinson, Mississauga, Ontario, Canada). HT29–hCG cells were generated by transfection of a pCMV-hCG expression vector (gift of Dr. Bert Vogelstein, John Hopkins Medical Institutions, Baltimore, MD) into HT29 cells using LipofectAMINE 2000 (Life Technologies, Inc.) followed by selection in G418. Medium was collected from isolated individual clones and screened for levels of the secreted β-subunit of hCG using the pathozone-free β-hCG enzyme immunoassay kit (Omega Diagnostics, Alloa, Scotland, United Kingdom). Selected positive clones were infected i.p. into nu/nu mice to test for hCG secretion into the urine [for use as a soluble surrogate (molecular) marker of tumor progression and disease burden, as well as response to therapy; Ref. 28]; urine was collected weekly and assayed as above for the presence of hCG, normalized to levels of creatinine (measured using creatinine detection kit from Sigma Diagnostics).

Experiments in FgR Knockout Mice. Wild-type nu/nu, FgRRII–/−, or FgRRII+/−/−nu/nu mice were injected i.p. with a single cell suspension of 5 × 106 HT29–hCG cells in 0.2 ml of PBS. Treatments were given as follows: (a) FgRRII–/− – single-standard dose (Fig. 6), 7 days after xenograft injection, mice were injected i.p. with 0.2 ml of PBS +/− 20 μg SHE7–7–(b), FgRRII–/− biweekly treatment with subtherapeutic (1/10 of standard) dose (Fig. 7), beginning 7 days after xenograft injection, mice were injected i.p. with 0.2 ml of PBS +/− 2 μg SHE7–7 every 2 weeks; (c) FgRRII–/− weekly treatment (Fig. 8), beginning 7 days after xenograft injection, mice were injected weekly i.p. with 0.2 ml of PBS +/− 20 μg SHE7–7–(d) mice were sacrificed when urine samples were collected from isolated individual clones and screened for levels of the secreted β-subunit of hCG using the pathozone-free β-hCG enzyme immunoassay kit (Omega Diagnostics, Alloa, Scotland, United Kingdom). Selected positive clones were infected i.p. into nu/nu mice to test for hCG secretion into the urine [for use as a soluble surrogate (molecular) marker of tumor progression and disease burden, as well as response to therapy; Ref. 28]; urine was collected weekly and assayed as above for the presence of hCG, normalized to levels of creatinine (measured using creatinine detection kit from Sigma Diagnostics).

RESULTS

A Neutralizing Antibody against E-Cadherin Disrupts Preformed Spheroids in Vitro. We have demonstrated previously the ability of SHE7–7 (26), a particularly effective antihuman E-cadherin neutralizing antibody, to prevent spheroid formation by a number of E-cadherin-expressing human cancer cell lines, including colon (HT29 and DLD-1), breast (MCF-7 and BT-20), and lung (L23) carcinoma lines (19). However, in a clinical setting it is critical that an antiadhesive can disrupt pre-existing adhesive interactions rather than simply prevent their occurrence. As such, we examined the ability of the SHE7–7 antibody to disrupt preformed spheroids of HT29 and CaOV-3, by allowing adhesive interactions to take hold for 5 days (Fig. 1, A and G) before exposing the spheroids to SHE7–7.

Within 6 h of exposure to 1 μg/ml SHE7–7, the liberation of single cells from the periphery of intact spheroids could already be seen (Fig. 1B), and essentially complete disaggregation into a single cell suspension was achieved after 24 h in both cell lines (Fig. 1, D and H). Similarly, exposure to 0.7 μg/ml SHE7–7 F(ab′)2 fragments resulted in complete disaggregation after 24 h (Fig. 1E); F(ab′)2 fragments were given at 70% of the dose of the complete antibody, reflecting the difference between their relative masses. Fig. 1 demonstrates this antiadhesive effect on small spheroids, comprised of 1000 cells; however, it should be noted that complete disruption of spheroids of up to 20,000 cells was achieved under the same experimental conditions (data not shown).
In contrast, 24-h exposure of HT29 spheroids to an isotype-matched (IgG2a) nonspecific control antibody (not shown) or to an isotype-matched monoclonal antibody against the human MHC class I (which binds to the cell surface but should not affect cell-cell interactions) had no observable effect on adhesion (Fig. 1F). Finally, disruption of spheroids by SHE78–7 (whole Ab or F(ab′)₂) did not cause cell death, confirming our previous finding that prevention of cell-cell adhesion by SHE78–7 led to a stimulation of growth in several human cancer cell lines, including HT29 (19).

**A Neutralizing Antibody against E-Cadherin Disrupts Multicellular Aggregates of HT29 in an i.p. Ascites Tumor Xenograft Model in Vivo.** Having established the ability of the SHE78–7 antibody to disrupt preformed aggregates of cells in vitro, we next sought to determine whether it could display similar antiadhesive properties in vivo in an i.p. ascites tumor model. i.p. xenografts were established in nude mice via exposure to SHE78–7. Five-day-old, 1000-cell spheroids of HT29 (A) or CaOV-3 (G), in round-bottomed plates, were exposed to 1 μg/ml SHE78–7 (B–D and H), 0.7 μg/ml SHE78–7 F(ab′)₂ fragments (E), or 1 μg/ml α-hMHC-I mAb (F), and photographed after 6 (B), 12 (C), or 24 h (D–F and H) under ×100 (A–F) or ×40X (G and H) magnification. Bar = 200 μm (A–F) or 500 μm (G and H).

Fig. 1. Disruption of preformed spheroids of HT29 (A–F) and CaOV-3 (G and H) in vitro via exposure to SHE78–7. Five-day-old, 1000-cell spheroids of HT29 (A) or CaOV-3 (G), in round-bottomed plates, were exposed to 1 μg/ml SHE78–7 (B–D and H), 0.7 μg/ml SHE78–7 F(ab′)₂ fragments (E), or 1 μg/ml α-hMHC-I mAb (F), and photographed after 6 (B), 12 (C), or 24 h (D–F and H) under ×100 (A–F) or ×40X (G and H) magnification. Bar = 200 μm (A–F) or 500 μm (G and H).

Mice treated with PBS alone showed no evidence of ascites tumor cluster disruption (Fig. 2A). Injection of 10 μg SHE78–7 resulted in partial disruption, although the effect was incomplete (not shown); however, treatment with 20 μg SHE78–7 effectively disrupted the tumor cell-cell interaction, as few, if any, multicellular aggregates were recovered after 48 h (Fig. 2B). No additional antiadhesive effect was seen in mice treated with 40 μg SHE78–7; as such, 20 μg was chosen as an appropriate dosage for use in subsequent in vivo experiments. When 14 μg of the F(ab′)₂ fragment (i.e., 70% of 20 μg, the effective dose of intact SHE78–7) was injected in place of the whole Ab, i.p. tumor clumps were similarly disrupted (data not shown).

To ensure that the disruption was exclusively the result of targeting E-cadherin, this experiment was repeated, replacing 20 μg SHE78–7 with 20 μg of an isotype-matched α-hMHC-I Ab (which binds to HT29 but is nondisruptive in vitro). As expected, when peritoneal contents were examined 48 h after injection of the α-hMHC-I Ab, tumor cell clusters were indistinguishable from those of PBS-treated mice (data not shown).

SHEL78–7-mediated Disaggregation of i.p. Ascites Tumor Clusters in Vivo in Nude Mice Prolongs Survival in an Fc- and Antiadhesion-dependent Manner. Prevention of E-cadherin-mediated adhesion in HT29 grown in three-dimensional culture frees cells from...
contact-mediated growth inhibition, thereby causing an increase in cell proliferation (19). As such, in the absence of a host immune response, one might expect SHE78–7-mediated disaggregation of i.p. HT29 ascites tumor clusters in vivo to accelerate disease progression by causing the liberated cancer cells to reproduce more quickly than they would otherwise.

However, as seen in Fig. 3, a single i.p. treatment with 20 μg SHE78–7, 1 week after establishment of an i.p. HT29 xenograft, caused a significant (P < 0.0001) increase in survival in nude mice when compared with treatment with PBS alone (n = 15). Median survival times for the PBS and SHE78–7-treated groups were 56 and 80 days, respectively (Fig. 3), and were effectively reproduced in two independent experiments.

Subsequent experiments (Fig. 4) demonstrated that this increase in survival is enhanced additionally with repeated treatments (every 2 weeks) of SHE78–7 (Fig. 4, A and B; SHE78–7; whole Ab versus PBS). In i.p. xenograft models using two independent clonal derivatives of HT29, namely HT29-GFP (Fig. 4A) and HT29-hCG (Fig. 4B), biweekly administration of 20 μg SHE78–7 led to significant increases in survival over PBS-treated controls (P = 0.0007 and P = 0.0198, respectively), with median survival times of 190 days (Fig. 4A) and 106 days for SHE78–7-treated mice (Fig. 4B) compared with 50 and 47 days in the corresponding PBS-treated mice.

Also, at the time of sacrifice, 80% of PBS-treated mice in each experiment displayed profuse peritoneal bleeding, indicative of advanced i.p. disease, whereas no HT29-GFP-carrying mice and only 1 of 5 HT29-hCG-carrying mice treated with SHE78–7 developed peritoneal bleeding at any time. This suggests that the antitumor activity of SHE78–7 is particularly effective with respect to bona fide i.p. disease.

We hypothesized that this antitumor effect of SHE78–7, seen only in vivo, was attributable, at least in large part, to the ability of the antibody to recruit and/or enhance a host antitumor immune response. Although nude mice lack functional T-cell immunity, they maintain...
populations of ADCC effector cells, such as natural killer cells and macrophages, and a functional complement cascade. As such, nude mice are capable of mounting an Fc-dependent immune response to antibodies of murine origin, such as SHE78–7, and the cells to which they bind.

To test whether the SHE78–7 antibody was, in fact, eliciting an Fc-dependent immune response, we included an additional group of mice in each of the aforementioned survival experiments (Fig. 4), which were treated biweekly with 14 µg of the F(ab')2 fragment of SHE78–7. Because the F(ab')2 fragment of SHE78–7 is capable of causing complete disaggregation of i.p. ascites tumor cell clusters in vivo, it would provide a survival advantage equivalent to that conferred by the intact antibody only if treatment of i.p. xenografts of HT29 with SHE78–7 was causing tumor cell death in an Fc-independent manner. However, as shown in Fig. 4, treatment with the F(ab')2 fragment provided no significant survival advantage over PBS treatment in mice carrying xenografts of either HT29-GFP (Fig. 4A; \( P = 0.984 \)) or HT29-hCG (Fig. 4B; \( P = 0.6408 \)) median survival times of F(ab')2-treated mice were 55 and 65 days, respectively.

We hypothesized additionally that SHE78–7 is uniquely effective in its role of recruiting a host immune response because of its potent antiadhesive effects, which may enable it to act simultaneously as an immunosensitizer, enhancing any such response by increasing accessibility of target cells for immune effectors. To test this hypothesis, we included a group of mice in each survival experiment that were treated biweekly with 20 µg of an isotype-matched, HT29-binding, nondisruptive, α-hMHC-I monoclonal Ab. As predicted, SHE78–7 was significantly more effective than the α-hMHC-I Ab at prolonging survival of mice carrying i.p. xenografts of either HT29-GFP (Fig. 4A) or HT29-hCG (Fig. 4B). However, it should be noted that treatment with α-hMHC-I Ab did provide a significant survival advantage over PBS treatment in mice carrying HT29-GFP xenografts (Fig. 4A), confirming that this Ab is still capable of recruiting a limited Fc-dependent immune response. This was not the case in mice with HT29-hCG xenografts, likely because the relative antitumor capabilities of both the α-hMHC-I and SHE78–7 Abs were less pronounced in this model system, perhaps as a result of clonal differences between the hCG- and GFP-expressing HT29 lines. Nonetheless, the therapeutic superiority of the SHE78–7 Ab over the α-hMHC-I Ab in both systems strongly suggests that the antiadhesive ability of SHE78–7 is important, if not critical, to its efficacy as an immunosensitizer for an Fc-dependent immune response.

We subsequently reasoned that if, indeed, both the presence of an Fc portion and antiadhesive activity were necessary for SHE78–7 to act as a highly effective immunosensitizing agent, a similarly notable anticancer effect should, in theory, be achievable through the use of α-hMHC-I antibodies, which would enable recruitment of an Fc-mediated immune response, in combination with antiadhesive F(ab')2 fragments of SHE78–7. As shown in Fig. 5A, this “combination therapy” regimen does indeed provide an enhanced survival advantage to mice carrying HT29-hCG i.p. xenografts that differs significantly from that conferred by PBS treatment (\( P = 0.0334 \)), or monotherapy with either α-hMHC-I Ab (\( P = 0.0020 \)) or SHE78–7 F(ab')2 fragments (\( P = 0.0013 \)) alone. The increased survival conferred by this combination therapy was statistically similar to that resulting from treatment with intact SHE78–7 antibodies.

In addition, pooled urine samples were collected weekly from each group of mice for tumor marker evaluation; levels of hCG secreted by the transplanted tumor cells into the urine of xenograft tumor-bearing mice were normalized to urinary creatinine as a marker of renal function and used to measure tumor progression (28). As shown in Fig. 5B, the levels of hCG detected were indicative of substantially delayed disease progression in mice treated with either intact SHE78–7 antibodies or the combination of α-hMHC-I Abs + SHE78–7 F(ab')2 fragments, relative to all of the other treatment groups. Together with the survival data, this clearly demostrates the importance of antiadhesion to the antibody-mediated, Fc-dependent antitumor immune response recruited by SHE78–7.

It is now known that the FcRIIB is necessary for the optimal expression of the FcγRIIa activating receptor (29). The rationale for the use of such subtherapeutic dosing is based on the observation that treatment of mice carrying s.c. xenografts of BT474/M1 breast carcinoma with subtherapeutic doses of Herceptin (i.e., 10-fold less than the established therapeutic dose of SHE78–7, i.e., 2 µg instead of 20 µg). The rationale for the use of such subtherapeutic dosing is based on the observation that treatment of mice carrying s.c. xenografts of BT474/M1 breast carcinoma with subtherapeutic doses of Herceptin (i.e., 10-fold less than the established therapeutic dose of SHE78–7, i.e., 2 µg instead of 20 µg). The rationale for the use of such subtherapeutic dosing is based on the observation that treatment of mice carrying s.c. xenografts of BT474/M1 breast carcinoma with subtherapeutic doses of Herceptin (i.e., 10-fold less than the established therapeutic dose of SHE78–7, i.e., 2 µg instead of 20 µg). The rationale for the use of such subtherapeutic dosing is based on the observation that treatment of mice carrying s.c. xenografts of BT474/M1 breast carcinoma with subtherapeutic doses of Herceptin (i.e., 10-fold less than the established therapeutic dose of SHE78–7, i.e., 2 µg instead of 20 µg). The rationale for the use of such subtherapeutic dosing is based on the observation that treatment of mice carrying s.c. xenografts of BT474/M1 breast carcinoma with subtherapeutic doses of Herceptin (i.e., 10-fold less than the established therapeutic dose of SHE78–7, i.e., 2 µg instead of 20 µg).

To determine which of these Fc-dependent processes, ADCC or CMC, factor most prominently into SHE78–7-mediated antitumor activity, we performed additional in vivo experiments, using an i.p. xenograft model as described above, comparing the therapeutic efficacy of SHE78–7 in wild-type nude mice versus nude mice that lacked expression of either the inhibitory receptor FcγRIIB or the activating receptor FcγRIII. In the first of these experiments (Fig. 6), a single i.p. administration of 20 µg SHE78–7 was given to wild-type or FcγRIIB−/− nude mice carrying i.p. xenografts of HT29-hCG, 1 week after xenograft injection. As shown in Fig. 6A, whereas SHE78–7 treatment significantly prolonged survival of wild-type mice compared with a group of PBS-treated controls (\( P = 0.0136 \)), this effect was greatly enhanced in FcγRIIB−/− mice (\( P = 0.0246 \)), with all of the mice surviving beyond 100 days; median survival times for PBS- and SHE78–7-treated wild-type mice were 54 and 71 days, respectively. In addition, we found that tumor growth through the peritoneal wall at the xenograft/treatment injection site was significantly slower in FcγRIIB−/− mice than in wild-type mice (\( P = 0.0105 \); Fig. 6B). However, such measurements fail to take into account any i.p. tumor growth that cannot be seen from the exterior of the mice. For this reason, levels of hCG, secreted by tumor cells into the urine of tumor-bearing mice, were measured to give an indication of complete tumor progression. In so doing, we found that the levels of hCG detected were notably greater in wild-type mice versus FcγRIIB−/− mice (Fig. 6C), indicating more advanced disease progression in the former. The apparent exponential increases in hCG levels (Fig. 6C), in contrast to the linear growth curves associated with injection site tumor growth (Fig. 6B), suggest that the former may, in fact, be more reflective of true disease progression and/or imminent death.

In a separate experiment (Fig. 7), wild-type and FcγRIIB−/− nude mice carrying HT29-hCG xenografts i.p. were treated biweekly, rather than once only as in Fig. 6, although the treatments used were 10-fold less than the established therapeutic dose of SHE78–7, i.e., 2 µg instead of 20 µg. The rationale for the use of such subtherapeutic dosing is based on the observation that treatment of mice carrying s.c. xenografts of BT474/M1 breast carcinoma with subtherapeutic doses of Herceptin (i.e., 10-fold less than the dose shown to be effective in wild-type mice), was sufficient to achieve a remarkable tumor growth delay in FcγRIIB−/− mice but not in corresponding wild-types (25). Similarly, we have found that biweekly administration of 2 µg of SHE78–7 significantly delayed the growth of HT29-hCG tumors in FcγRIIB−/− mice compared with wild-type (\( P = 0.0134 \); Fig. 7A). As in the previous experiment, levels of urinary hCG were notably
different between the two groups (Fig. 7B) and were reflective of bona fide i.p. tumor growth delay in F\textsubscript{c}RIIB \textasciitilde mice compared with wild-types. This variable response to treatment with SHE78–7 is additionally illustrated by the fact that by week 9, 100% of wild-type mice, but no F\textsubscript{c}RIIB \textasciitilde mice, showed signs of peritoneal bleeding, which is an indication of advanced i.p. disease; on termination of the experiment at week 14, only 1 of 5 F\textsubscript{c}RIIB \textasciitilde mice had such peritoneal bleeding.

Whereas these experiments in F\textsubscript{c}RIIB \textasciitilde mice seem to implicate ADCC as the predominant F\textsubscript{c}-dependent immune response ultimately responsible for the antitumor effect of SHE78–7, we sought to verify our findings by using a different, yet complimentary, knockout model; specifically, we used mice that retained expression of F\textsubscript{c}RIIB, but instead lacked expression of an activating receptor, F\textsubscript{c}RIII. Groups of wild-type or F\textsubscript{c}RIII \textasciitilde mice carrying i.p. HT29-hCG xenografts were treated weekly with PBS \textasciitilde 20 μg SHE78–7, rather than biweekly, to maximize any F\textsubscript{c}-mediated responses to the mAb. In so doing, we found that the response of wild-type mice to weekly treatment with SHE78–7, as assessed by transperitoneal tumor growth (Fig. 8A), was significantly \( P = 0.0238 \) greater than that of F\textsubscript{c}RIII \textasciitilde mice; in fact, in F\textsubscript{c}RIII \textasciitilde mice, SHE78–7 was no more effective than PBS alone (\( P = 0.4578 \); data not shown) at slowing tumor growth. Again, we observed a vast difference in the levels of hCG secreted by xenograft cells in each of the two groups (Fig. 8B), demonstrating a profound difference in therapeutic efficacy with respect to complete (i.e., including disseminated, externally unobservable) disease.

Taken together, these data suggest that SHE78–7 does indeed mediate its antitumor effects predominantly via enhancement of ADCC, through F\textsubscript{c}RIII. Furthermore, F\textsubscript{c}RIIB was shown to negatively regulate this response, as in the absence of this receptor, the antitumor effect of SHE78–7 was greatly enhanced.

DISCUSSION

We have investigated the use of an antiadhesive mAb as a means of specifically targeting an effector immune response to human cancer cell xenografts \textit{in vivo}, while simultaneously acting as an immuno-sensitizer by disrupting the multicellular aggregates in which the cells grow. We show that an antiadhesive Ab targeted at the cell adhesion molecule E-cadherin is capable of prolonging the survival of nude mice bearing ascites aggregates of HT29 human colorectal carcinoma, in a manner that is dependent on both its involvement in ADCC and its antiadhesive properties.

Antiadhesives have been championed previously as putative therapeutic agents in cancer treatment for a number of reasons, including their potential to interfere with adhesion critical for metastatic spread (31, 32), and their ability to cause chemo- and/or radiosensitization of therapy-resistant tumors (4, 7). However, to the best of our knowl-
ANTIADHESIVE ANTIBODY ENHANCES ADCC

edge, this report is the first demonstration of the use of an antiadhesive strategy to sensitize cancers to immune-mediated destruction.

To date, many efforts to improve antibody-mediated treatment of cancer have centered on finding means by which to avoid immune neutralization of exogenous antibodies by, for example, engineering chimeric or humanized antibodies (20). However, recent work by Clynes et al. (25) showed that two mAbs approved for clinical use in cancer treatment, namely Rituaxan (rituximab) and Herceptin (trastuzumab), were significantly less effective as antitumor agents when used as an antiadhesive agent, it would have additional putative therapeutic value as it could not only passively sensitize target cells to host defense mechanisms, but could become actively involved in immune-mediated antitumor activity.

However, it should be noted that high interstitial pressure gradients within a large solid tumor mass (Ref. 10; as opposed to a disseminated cancer as modeled in the experiments described herein) may sufficiently hinder the diffusion of an antibody, even one with antiadhesive function, as to seriously limit its therapeutic value in such a context. Whereas we feel that our data suggest that antiadhesives could aid, at least in part, in overcoming such diffusional constraints, additional experiments, i.e., using solid tumors, would be necessary to fully elucidate the extent to which this may or may not occur.

We have found that SHE78–7 (26), a monoclonal antibody raised...
against the human homophilic cell adhesion molecule E-cadherin, is one such antibody capable of acting as an antiadhesive. We have shown that not only can SHE78–7 prevent cell-cell adhesion by a number of human cancer cell lines in spheroid culture in vitro (19), but can in fact disrupt preformed spheroids of HT29 and CaOV-3 ovarian carcinoma in vitro, bringing us closer to a clinically relevant scenario in which an intact cancerous mass could be disrupted. Such disruptive ability is not unique to this particular mAb; for example, exposure to 1 mg/ml of MoAF-6D6, a mAb raised against a cell surface-associated adhesive factor isolated from rat ascites hepatoma AH136B cells, caused disruption, in vitro, of preformed multicellular aggregates of AH136B grown in vivo i.p. in Donryu rats (34). Naturally, such antiadhesive ability must also be functional in vivo before any claims can be made with respect to therapeutic potential. Our in vivo work has implicated Fc-dependent host immune responses (37), and that cell-cell contact can provide protection against apoptosis in colonic epithelial cells (38) and LIM1863 colon carcinoma cells (39). However, the antitumor effect of SHE78–7 against HT29 is unlikely the direct result of an induction of apoptosis via the disruption of cell-cell contacts, for two main reasons: (a) we have found that neither the prevention (19) nor disruption of E-cadherin-mediated adhesion induces apoptosis of HT29 growing in three-dimensional culture in vitro; and (b) F(ab′)2 fragment of SHE78–7, although equivalent to the parent antibody with respect to antiadhesive activity, was unable to confer any survival advantage on mice under the same experimental conditions in which the whole antibody demonstrates antitumor activity. Therefore, we concluded that antiadhesion was necessary, but not sufficient, for the observed antitumor activity of SHE78–7. In fact, the failure of the SHE78–7 F(ab′)2 fragment to provide any significant survival advantage, unless coupled with an intact α-hMHC-I mAb, directly implicated an Fc-dependent host immune response in the antitumor activity of the whole antibody.

Nude mice, although lacking in functional T-cell-mediated immunity, retain the ability to mount Fc-dependent immune responses mediated by effector cells (ADCC) and complement (CDC). Recent work has implicated FcγRIIB as an essential modulator of ADCC involving therapeutic monoclonal antibodies (25). However, this or any other Fcγ-receptors are not required for CDC. As such, to determine which of these mechanisms was predominantly responsible for the antitumor activity of SHE78–7 in vivo, we tested the impact of the antibody on the growth of i.p. xenografts of HT29-hMHC in FcγRIIB−/− and FcγRIII−/− nude mice, in comparison to wild-type nudes, reasoning that if ADCC was the more important of the two mechanisms in this case, the antibody should demonstrate added potency in mice lacking FcγRIIB, whereas its efficacy should be compromised in mice lacking FcγRIII.

Our results show FcγRIIB−/− mice do indeed mount an increased response to SHE78–7 treatment, both at full and subtherapeutic doses, compared with corresponding wild-type mice. In both treatment sce-
narios, tumor growth at the injection site(s), a characteristic feature of this model system, was significantly delayed in F\textsubscript{\gamma RII}−/− mice. When mice received only a single treatment with 20 \mu g SHE78−7 (Fig. 5), this growth delay was accompanied by a significant prolongation of survival of F\textsubscript{\gamma RII}−/− mice.

In addition, SHE78−7 treatment proved to be ineffective in F\textsubscript{\gamma RIII}−/− mice, despite being administered at twice the frequency required to see a profound antitumor effect in wild-type mice. Indeed, tumor growth proceeded seemingly unimpeded in the knockouts, in direct contrast to the growth hindrance caused by SHE78−7 treatment in wild-type mice.

Overall, this study supports the hypothesis that antiadhesives may be used as immunosensitizers with which to improve the efficacy of monoclonal antibody-mediated therapy of cancer. One important, and obvious, caveat to such a claim concerns the use of human E-cadherin as a target molecule in the present study. Numerous studies have shown that E-cadherin is down-regulated or absent in many human carcinomas, whereas many ovarian cancers have been found to gain significant expression thereof (41, 42, 43). Indeed, it was for this reason that we chose an in vivo model for this work that mimicked, in some respects, advanced ovarian cancer. However, more importantly, this work may be viewed as a demonstration of the principle that cell adhesion, be it mediated by cadherins, integrins, or other adhesion molecules, may represent a hindrance to the therapeutic efficacy of monoclonal antibodies and should, therefore, be taken into account when investigating means by which to improve monoclonal antibody-mediated anticancer therapy. In this regard, there are certain cell adhesion molecules that are strongly up-regulated in cancer cells, compared with their normal cell counterparts, e.g., ICAM-1 and MUC-18 in melanoma (44), or N-cadherin or CD44 in a number of malignancies (45, 46), among others. This differential expression may provide a therapeutic window for the use of antibodies directed against such targets, provided that the molecules mediate, in a significant way, tumor cell-cell adhesion.

**ACKNOWLEDGMENTS**

We thank Kazuki Yamamoto of Takara Shuzo Co., Shiga, Japan, for generously providing the SHE78−7 antibody and Fab\textsubscript{\gamma} fragments thereof. We also thank Victoria Lappi for technical assistance with the experiments in F\textsubscript{\gamma RII}−/− mice, Dr. Giannoula Klement and Dr. Giulio Francia for their critical review of this manuscript, and Lynda Woodcock and Cassandra Cheng for their excellent administrative assistance.

**REFERENCES**

Disruption of Cell-Cell Adhesion Enhances Antibody-dependent Cellular Cytotoxicity: Implications for Antibody-based Therapeutics of Cancer

Shane K. Green, Mikael C. I. Karlsson, Jeffrey V. Ravetch, et al.


Updated version  Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/62/23/6891

Cited articles  This article cites 46 articles, 12 of which you can access for free at: http://cancerres.aacrjournals.org/content/62/23/6891.full#ref-list-1

Citing articles  This article has been cited by 16 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/62/23/6891.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.